ABSTRACT: Backgr ound : Vaccination is an important method for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. There is currently a lack of real-world clinical data regarding the safety and efficacy of coronavirus disease 2019 (COVID- 19) vaccines with respect to plaque psoriasis treatment involving tumor necrosis factor (TNF)-α and interleukin (IL)- 17A inhibitors. Method s: We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID- 19 vaccine (either BBIBP-CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF- α inhibitors or IL- 17A inhibitors) or acitretin. Routine blood tests were used to assess safety; the psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) were used to assess efficacy. Results: After inactivated COVID- 19 vaccination, biologics retained considerable advantages in terms of improving skin lesions (measured by PASI) and quality of life (measured by DLQI), compared with conventional treatment (p<0.05 and p<0.01, respectively). Routine blood tests and hepatorenal function analyses suggested that inactivated SARS-CoV-2 vaccines did not alter the safety of biologics treatment (p>0.05). Conclusions: Inactivated SARS-CoV-2 vaccines do not have significant impacts on the safety and efficacy of biologics (TNF-α inhibitors or IL- 17A inhibitors) in patients with moderate to severe plaque psoriasis.